SANDOSTATINE LP 30 mg (octreotide), somatostatin analogue
ONCOLOGY - New indication
Opinions on drugs - Posted on Dec 01 2016
Reason for request
Extension of indication
Substantial clinical benefit in the treatment of advanced, non-progressive neuroendocrine tumours of the midgut or unknown primary site with a Ki-67 index ≤ 10%, constituting a possible alternative to simple monitoring.
Insufficient clinical benefit for advanced and progressive neuroendocrine tumours of the midgut or unknown primary site.
- SANDOSTATINE LP 30 mg now has indication in the treatment of advanced neuroendocrine tumours (NETs) of the midgut or of unknown primary origin where non-midgut sites of origin have been excluded.
- Its efficacy compared with placebo has been demonstrated in terms of mean time to progression or tumour-related death. No benefit on overall survival was demonstrated
- No data in patients with this type of progressive tumour is available: its therapeutic value in progressive NETs is not established.
Clinical Added Value
|no clinical added value||
Évaluation des médicaments